Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy

Abstract

Purpose: We performed a head-to-head comparison of the PHI (Prostate Health Index) and PCA3.

Materials and methods: We evaluated PHI and PCA3 performance in 211 patients undergoing initial (116) or repeat (95) prostate biopsy. Multivariable logistic regression analysis was done using the AUC to test the accuracy of PHI and PCA3 for predicting prostate cancer in the overall population and in each setting. Decision curve analysis was used to compare the clinical benefit of different models.

Results: Overall, the AUC of the PHI (0.70) was significantly higher than the AUC of PCA3 (0.59), total prostate specific antigen (0.56) and free-to-total prostate specific antigen (0.60) (p = 0.043, 0.002 and 0.037, respectively). PHI was more accurate than PCA3 for predicting prostate cancer in the initial setting (AUC 0.69 vs 0.57) and in the repeat setting (AUC 0.72 vs 0.63), although no statistically significant difference was observed. Including PCA3 in the base multivariable model (prostate specific antigen plus free-to-total prostate specific antigen plus prostate volume) did not increase predictive accuracy in either setting (AUC 0.79 vs 0.80 and 0.75 vs 0.76, respectively). Conversely, including PHI in the base multivariable model improved predictive accuracy by 5% (AUC 0.79 to 0.84) and 6% (AUC 0.75 to 0.81) in the initial and repeat prostate biopsy settings, respectively. On decision curve analysis the highest net benefit was observed when PHI was added to the base multivariable model.

Conclusions: PHI and PCA3 provide a significant increase in sensitivity and specificity compared to all other examined markers and they may help guide biopsy decisions. PCA3 does not increase the accuracy of predicting prostate cancer when PHI is assessed.

Keywords: BMM; DCA; DRE; HGPIN; PBx; PCA3; PCa; PCa gene 3; PSA; [−2]proPSA; base multivariable model; biopsy; decision curve analysis; digital rectal examination; fPSA; free PSA; high grade prostatic intraepithelial neoplasia; p2PSA; prostate; prostate biopsy; prostate cancer; prostate cancer antigen 3, human; prostate specific antigen; prostate-specific antigen; prostatic neoplasms; tPSA; total PSA.